USP1

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

Retrieved on: 
Thursday, April 4, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, WEE1, AACR, Infection, DDR, USP1, Pharmaceutical industry

Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

Key Points: 
  • Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.
  • “Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1.
  • These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations.” - Angela Zubel, Chief Development Officer at Debiopharm

Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432

Retrieved on: 
Tuesday, March 26, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, DUB, Debiopharm, Therapy, Infection, USP1, DNA, DDR, Cancer, Drug discovery, Vaccine

The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.

Key Points: 
  • The agreement will support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432.
  • Under the terms of the agreement, Ubiquigent will deploy its DUB-focused platform, combined with its deep understanding of the DUB field, to develop novel target engagement assays to support Debio-0432 as it approaches the clinic.
  • Currently, in late-stage preclinical development, Debio 0432 is a small molecule with best-in-class potential that could be deployed to combat multiple tumour types.
  • “We are delighted to enter this agreement with Debiopharm, supporting the development of its advanced USP1 inhibitor programme.

Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
SAN, PARG, San Diego Convention Center, Blacksmith, FEN1, USP1, AACR, ATR, PARP, Pharmaceutical industry

SAN DIEGO, March 6, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.

Key Points: 
  • SAN DIEGO, March 6, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.
  • Details of the poster presentation are as follows:
    Title: "Small molecule inhibitor of FEN1 nuclease utilizing a novel metal binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR"

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Molecule, Royalty payment, Conference, Liver disease, Calendar, Breast, Immunotherapy, RCC, PIN, ASCO, NHT, Progression-free survival, Safety, FDA, PLK4, ADC, ITT, PKMYT1, Associate, University, Baylor University, PARP, USP1, Society, Neck, Science, Acquisition, Biology, Superior, Huntsman Cancer Institute, Dean (education), Metastasis, PFS, Translational research, Drug development, Distinguishing, Head, Food, NET, Baylor College of Medicine, Cancer, Share repurchase, BIRC, OS, SCCHN, Neoplasm, Congress, National Cancer Institute, Abbreviated New Drug Application, Research, Docetaxel, Translation, Prostate cancer, Therapy, ESMO, Education, Experiment, Checkmate, Pharmaceutical industry

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
Sunday, January 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Associate, Baylor College of Medicine, PKMYT1, BRCA, FDA, Breast, Progression-free survival, Society, Insilico Medicine, Cancer, Distinguishing, Translational research, Neck, PLK4, Workforce, Conference, Translation, Biology, IND, Colorectal cancer, MSN, NHT, University, PARP, Doctor of Philosophy, Calendar, District court, Harvard University, Immunotherapy, Food, Johnson & Johnson, NET, Huntsman Corporation, Cell adhesion, Therapy, TKI, USP1, Neoplasm, Experiment, Patient, NCI, Corporation, Baylor University, Huntsman Cancer Institute, Research, Acquisition, Dean (education), Education, Pnet, Head, Shareholder, Share repurchase, PFS, ADC, Pharmaceutical industry

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

Retrieved on: 
Wednesday, January 3, 2024
Cell death, Survival, Breast, FDA, Cancer, DNA, Therapy, USP1, Pharmacokinetics, PARP, Patient, Safety, Pharmaceutical industry

“Dosing the first patient in the TNG348 phase 1/2 trial is an important milestone for us and for patients with advanced ovarian, breast and certain other cancers.

Key Points: 
  • “Dosing the first patient in the TNG348 phase 1/2 trial is an important milestone for us and for patients with advanced ovarian, breast and certain other cancers.
  • TNG348 has the potential to become a meaningful treatment for cancers caused by DNA damage repair pathways defects,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • HRD+ cancers, including BRCA1/2 mutations, represent up to 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers and 5% of pancreatic cancers.
  • In preclinical models, TNG348 has strong anti-tumor activity, inducing cell death and tumor growth inhibition in multiple xenograft models.

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Wednesday, November 8, 2023
Research, Breast, PRMT5, NSCLC, GBM, Cancer, Pembrolizumab, Georgetown University, Safety, SITC, Preclinical development, Head, Annual general meeting, University of California, San Diego Performance-Based Skills Assessment, USP1, Biotechnology, Genta (company), Lead, University, Therapy, Patient, Society for Immunotherapy of Cancer, Neuro-oncology, MTA, SNO, Conference, RCOR1, Immunotherapy, Clinical trial, MTAP, Nervous tissue, FDA, IND, Prostate cancer, Fast Track, Pharmacokinetics, STK11, Third Rock Ventures, Drug discovery, Collaboration, Carcinoma, Jannik Madum Andersen, Glioblastoma, FTD, Mutation, PARP, Pharmaceutical industry, Vaccine, Birth control, Petroleum, Arms industry, Biology

For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.

Key Points: 
  • For TNG462, we dosed the first patient in the phase 1/2 trial in July 2023.
  • Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023, San Diego, CA
    In November 2023, Tango scientists presented preclinical data highlighting the potential of TNG260 in STK11-mutant cancers.
  • AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11-15, 2023, Boston, MA
    In October 2023, Tango scientists presented five posters highlighting preclinical data from the precision oncology pipeline and synthetic lethality discovery platform.
  • The year-to-date increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, September 18, 2023
USP1, Abstract, AACR, Therapy, Conference, Pharmaceutical industry

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.

Key Points: 
  • BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts.
  • Title: Cancer-specific AI identifies multi-modal biomarkers of therapeutic response for 1,951 drugs including TNG348, a highly selective USP1 inhibitor